Mark W. Ledeboer

Discovery of a Novel, First-in-Class, Orally Bioavailable Azaindole Inhibitor (VX-787) of Influenza PB2

Michael P. Clark, Mark W. Ledeboer, Ioana Davies et al. · Journal of Medicinal Chemistry · 2014 · 207 citations · Full text

Influenza Pb2, Medicinal Chemistry, Medicine +13

Preclinical Activity of VX-787, a First-in-Class, Orally Bioavailable Inhibitor of the Influenza Virus Polymerase PB2 Subunit

Randal A. Byrn, Steven J.M. Jones, Hamilton B. Bennett et al. · Antimicrobial Agents and Chemotherapy · 2014 · 185 citations · Full text

Asymmetric Reduction. A Convenient Method for the Reduction of Alkynyl Ketones

Kathlyn A. Parker, Mark W. Ledeboer · The Journal of Organic Chemistry · 1996 · 118 citations

Chemical Engineering, Chemical Measurement, Engineering +12

Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases

Luc J. Farmer, Mark W. Ledeboer, Thomas Hoock et al. · Journal of Medicinal Chemistry · 2015 · 87 citations

Immunology, Immunologic Mechanism, Janus Tyrosine Kinases +16

Structural basis of TRPC4 regulation by calmodulin and pharmacological agents

Deivanayagabarathy Vinayagam, Dennis Quentin, Jing Yu-Strzelczyk et al. · eLife · 2020 · 66 citations · Full text